521 related articles for article (PubMed ID: 18652859)
1. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
Bortolato M; Chen K; Shih JC
Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
[TBL] [Abstract][Full Text] [Related]
2. Focusing on new monoamine oxidase inhibitors.
Bolasco A; Carradori S; Fioravanti R
Expert Opin Ther Pat; 2010 Jul; 20(7):909-39. PubMed ID: 20553094
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
4. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents.
Secci D; Bolasco A; Chimenti P; Carradori S
Curr Med Chem; 2011; 18(33):5114-44. PubMed ID: 22050759
[TBL] [Abstract][Full Text] [Related]
5. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Duarte P; Cuadrado A; León R
Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
7. [Monoamine oxidase as a target for drug action].
Drozak J; Kozłowski M
Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
[TBL] [Abstract][Full Text] [Related]
8. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
Deshwal S; Di Sante M; Di Lisa F; Kaludercic N
Curr Opin Pharmacol; 2017 Apr; 33():64-69. PubMed ID: 28528298
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
11. MAO-A and -B gene knock-out mice exhibit distinctly different behavior.
Shih JC; Chen K
Neurobiology (Bp); 1999; 7(2):235-46. PubMed ID: 10591056
[TBL] [Abstract][Full Text] [Related]
12. Drugs related to monoamine oxidase activity.
Fišar Z
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders.
Srivastava P; Sudevan ST; Thennavan A; Mathew B; Kanthlal SK
CNS Neurol Disord Drug Targets; 2024; 23(3):331-341. PubMed ID: 36872357
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.
Ramesh M; Muthuraman A
Comb Chem High Throughput Screen; 2020; 23(9):887-897. PubMed ID: 32208114
[TBL] [Abstract][Full Text] [Related]
15. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.
Carradori S; Secci D; Bolasco A; Chimenti P; D'Ascenzio M
Expert Opin Ther Pat; 2012 Jul; 22(7):759-801. PubMed ID: 22702491
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidases in development.
Wang CC; Billett E; Borchert A; Kuhn H; Ufer C
Cell Mol Life Sci; 2013 Feb; 70(4):599-630. PubMed ID: 22782111
[TBL] [Abstract][Full Text] [Related]
18. A second life for MAO inhibitors? From CNS diseases to anticancer therapy.
Sblano S; Boccarelli A; Mesiti F; Purgatorio R; de Candia M; Catto M; Altomare CD
Eur J Med Chem; 2024 Mar; 267():116180. PubMed ID: 38290352
[TBL] [Abstract][Full Text] [Related]
19. Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria.
Yoshino S; Hara A; Sakakibara H; Kawabata K; Tokumura A; Ishisaka A; Kawai Y; Terao J
Nutrition; 2011; 27(7-8):847-52. PubMed ID: 21371861
[TBL] [Abstract][Full Text] [Related]
20. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.
Bortolato M; Shih JC
Int Rev Neurobiol; 2011; 100():13-42. PubMed ID: 21971001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
